| | Study | Area | Afatinib | N | Female, n (%) | Age, years, median (range) | Mutations | Clinical stage | ECOG-PS, 0–1/≥2 | Histology |
| | Fujiwara A 2018 | Japan | First-line only | 28 | 19 (67.9) | 68 (37–82) | EGFR mutation | 8 IIIA, 3 IIIB, 16 IV, 1 recurrence | NR | 23 AD, 3 SCC, 2 other | | Hochmair MJ, 2018 | Global | First-line only | 204 | 110 (53.9) | 60 (30–86) | 150 Del19, 53 L858R, 1 uncommon | 197 IV, 7 missing | 153/31 (20 missing) | NR | | Jung HA, 2020 | Korea | First-line only | 61 | NR | NR | Uncommon EGFR mutation | NR | NR | NR | | Kanazu M, 2020 | Japan | Mixed | 12 | NR | NR | Uncommon EGFR mutation | 12 advanced | NR | NR | | Kuan FC, 2017 | Taiwan | First-line only | 81 | 42 (51.9) | 64 (37–83) | 48 Del19, 33 L858R | 7 IIIB, 74 IV | 70/11 | 81 AD | | Lim, J 2019 | USA | First-line only | 550 | 355 (64.5) | 63.3 ± 11.4 | EGFR mutation | NR | NR | NR | | Su VY, 2020 | Taiwan | First-line only | 99 | 52 (52.5) | 64.1 ± 10.8 | 53 Del19, 31 L858R, 15 uncommon | 4 IIIB, 95 IV | 89/10 | 96 AD, 3 non-AD | | Wu SG, 2020 (a) | Taiwan | First-line only | 36 | 27 (75) | 68.7 (43.0–86.1) | 36 uncommon | 32 IV, 4 recurrence | 32/4 | 36 AD | | Wu SG, 2020 (b) | Taiwan | First-line only | 91 | 44 (48.4) | 63 (37–83) | 59 Del19, 21 L858R, 11 uncommon | 83 advanced, 8 recurrence | NR | 91 AD |
|
|
Notes: NR, not reported; AD, adenocarcinoma; SCC, squamous cell carcinoma; ECOG-PS, Eastern Cooperative Oncology Group Performance Status.
|
